Ecklonia cava extract inhibits vascular smooth muscle cell migration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular diseases, such as atherosclerosis and vascular restenosis, often come with side effects like vascular injury, hepatotoxicity, and kidney damage, and existing natural substances have not been satisfactory in preventing or treating these conditions effectively.
Innovation Solution
A pharmaceutical composition using Ecklonia cava extract as an active ingredient, which is extracted using 45% to 50% ethanol, inhibits the migration and proliferation of vascular smooth muscle cells, reduces vascular inflammation, and improves blood vessel elasticity, thereby treating vascular diseases like atherosclerosis and restenosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-platelet agents, anticoagulants, cholesterol biosynthesis inhibitors, or anti-allergic agents are used to suppress arteriosclerosis or vascular restenosis, then the development of vascular disease is inhibited, but side effects such as vascular injury, hepatotoxicity, and kidney damage occur
Solution Approach 1:
The invention changes the chemical parameter by using a natural extract (Ecklonia cava) instead of synthetic pharmaceutical agents. The extract contains polyphenols and other bioactive compounds that inhibit vascular smooth muscle cell proliferation through natural biochemical pathways, avoiding the toxic side effects of conventional drugs while maintaining therapeutic effectiveness
Solution Approach 2:
The invention uses a natural extract from Ecklonia cava, a readily available marine resource, replacing expensive and toxic synthetic pharmaceuticals. The extract can be administered orally and provides sustained protection without the cumulative toxicity of long-term conventional drug therapy
2Productivity
If revascularization therapy such as coronary angioplasty or stenting is performed to treat atherosclerosis, then blood supply to organs is restored, but vascular restenosis occurs in about 40% of patients after 3 to 6 months
Solution Approach 1:
The Ecklonia cava extract is administered before and after revascularization procedures to prevent vascular restenosis. The extract pre-conditiones the vascular tissue by inhibiting smooth muscle cell proliferation pathways, and continues to prevent restenosis post-procedure, thereby maintaining long-term vessel patency while preserving the benefits of revascularization therapy
Solution Approach 2:
The Ecklonia cava extract acts as a biochemical intermediary between the mechanical revascularization procedure and the vascular tissue response. It modulates the inflammatory and proliferative responses to balloon catheter injury, preventing excessive smooth muscle cell migration and matrix deposition that lead to restenosis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to an Ecklonia cava extract, a preparation method thereof and a pharmaceutical composition for preventing or treating vascular diseases comprising the same as an active ingredient. The Ecklonia cava extract of the present invention was confirmed to have a medicinal effect on those factors involved in causing vascular diseases by the cell level experiments and the disease induced animal model experiments. Therefore, the Ecklonia cava extract of the present invention can be effectively used as an active ingredient of a pharmaceutical composition and a health functional food composition for the prevention, improvement or treatment of vascular diseases.